These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 29346478)

  • 1. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
    Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
    JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enasidenib in mutant
    Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
    Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
    Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
    Blood Adv; 2024 May; 8(10):2509-2519. PubMed ID: 38507688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission and response patterns in patients with mutant-
    Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
    Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
    Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
    Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
    Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
    Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
    Stein EM
    Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
    de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM
    Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
    Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
    Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
    DiNardo C
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enasidenib and ivosidenib in AML.
    Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
    Megherea O; Janes C; Kowalski A; Baron J; Ahn E; Soule A; Newman M
    Leuk Lymphoma; 2021 Dec; 62(13):3219-3225. PubMed ID: 34313176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
    Pollyea DA; Tallman MS; de Botton S; Kantarjian HM; Collins R; Stein AS; Frattini MG; Xu Q; Tosolini A; See WL; MacBeth KJ; Agresta SV; Attar EC; DiNardo CD; Stein EM
    Leukemia; 2019 Nov; 33(11):2575-2584. PubMed ID: 30967620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.